Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-10-15

Clinical Trial Update: A Study Evaluating the Persistency of Response With or Without Xolair (Omalizumab) After Long-term Therapy [Phase 4]

View source ↗

Summary

Phase 4 study evaluating the persistence of response after long-term omalizumab therapy in allergic asthma, comparing continued treatment with stopping.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Xolair (omalizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Allergic Asthma | Phase 4 | Status: COMPLETED | Results posted: 2014-10-15